Search
ADMA Biologics Inc
ADMAAdd to Watchlist
9.110USD
+0.160+1.79%
Close 09-18 16:00（ET）
2.05BMarket Cap
13.11P/E TTM
After-hours 16:26 (ET)9.080USD-0.025-0.28%
After-hours 16:26 (ET)ADMA Biologics Inc (ADMA) Stock Price Target & Forecast
Analyst Rating
Based on 4 analysts giving stock ratings to ADMA Biologics Inc in the past month.
Buy
0 Strong Buy
3 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
17.000USD+97.44%
ADMA Analyst Recommendation Trends
In the current month, ADMA has received 3 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ADMA average Analyst price target in the last month is 17.000.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
0
0
0
0
0
0
0
0
3
3
4
3
3
2
3
3
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
4
5
4
4
3
3
3
ADMA Analyst Rating for Peer Comparison
Updated: Sep 18, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Amgen Inc
AMGN
4
9
21
2
1
37
Biogen Inc
BIIB
7
17
12
1
0
37
Eli Lilly and Co
LLY
10
17
6
1
0
34
AbbVie Inc
ABBV
8
19
6
0
0
33
Pfizer Inc
PFE
5
6
19
1
1
32
Regeneron Pharmaceuticals Inc
REGN
6
15
11
0
0
32
Alnylam Pharmaceuticals Inc
ALNY
7
17
8
0
0
32
Merck & Co Inc
MRK
8
14
10
0
0
32
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Vertex Pharmaceuticals Inc
VRTX
9
16
5
0
1
31
Financial Forecasting
Based on analysts' estimates, ADMA EPS is projected to reach 0.195 in FY2026Q3, following reported EPS of 0.166 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
0.18
0.20
0.17
0.20
0.23
Actual
0.21
0.19
0.17
--
--
Surprise
+12.16%
-4.00%
-3.93%
--
--
FAQs
What is ADMA Biologics Inc's expected revenue for the next quarter?
ADMA Biologics Inc's expected revenue is 138.19M.
What is ADMA Biologics Inc's price target?
Analysts forecast that ADMA Biologics Inc's price target is USD 17.00, with the highest forecast at USD 21.00 and the lowest forecast at USD 12.00.
How have ADMA Biologics IncADMA's recent earnings per share performed?
The market expectation was USD 0.17, while ADMA Biologics IncADMA's earnings per share (EPS) for the previous quarter was USD 0.19. EPS for the next quarter is expected at USD 0.20.
What is the analyst rating for ADMA Biologics Inc?
Based on the ratings of ADMA Biologics Inc's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.